46 results about "Immune signaling" patented technology

The present invention relates to chimeric immune receptor molecules for reducing or eliminating tumors. The chimeric receptors are composed a C-type lectin-like natural killer cell receptor, or a protein associated therewith, fused to an immune signaling receptor containing an immunoreceptor tyrosine-based activation motif. Methods for using the chimeric receptors are further provided.

The present invention relates to chimeric immune receptor molecules for reducing or eliminating tumors. The chimeric receptors are composed a C-type lectin-like natural killer cell receptor, or a protein associated therewith, fused to an immune signaling receptor containing an immunoreceptor tyrosine-based activation motif. Methods for using the chimeric receptors are further provided.

The present invention relates generally to the Tlr4 signaling pathway specifically in the hematopoietic system and its contribution to insulin resistance of liver and adipose tissue. The hematopoietic component expressing Tlr4 is a principle propagator of immune signaling and results in insulin resistance. Furthermore, disclosed herein are methods and compositions for treating or preventing disorders associated with insulin resistance using a Tlr4 antagonist.

The invention belongs to the technical field of germplasm innovation of aquatic animals and particularly relates to a method for for breeding litopenaeus vannamei with WSSV (white spot syndrome virus) resistance on the basis of multi-marker combination assistance and an application of the multi-combination markers. SNP marker typing is performed on SNP loci of immune signaling pathways of the litopenaeus vannamei in sensitive groups and resistance groups with a high throughput typing technology, and 6 SNP molecular markers in significant correlation with WSSV resistance are obtained. The optimal resistance maker combination is obtained through screening with a multi-marker interaction analysis method and comprises nLvALF2g-89-A>G, Unigene34569g-97-T>C and TRAF6g-139-A>G, and four genotype combinations including AA-TT-AA, AA-CT-AA, AA-CT-AG and AG-CT-AA of the three markers show an obvious correlation advantage with the WSSV resistance. Candidate markers are provided for disease-resistant molecular breeding of prawns, one novel path is provided for molecular marker assistant resistance breeding of the prawns, and broad application prospect is realized in research of WSSV-resistance variety breeding of the prawns.

The invention relates to gelidium pacificum okam polysaccharide as well as a preparation method and application thereof, and belongs to the field of natural polymers. The invention provides a method for extracting and separating polysaccharide from gelidium pacificum okam, as well as a chemical structure and application of the polysaccharide. The average relative molecular weight is determined byutilizing GPC and the monosaccharide composition is analyzed by using GC-MS; the average relative molecular weight of the gelidium pacificum okam polysaccharide A-11 disclosed by the invention is found to be 28807Da and the gelidium pacificum okam polysaccharide A-11 is mainly prepared from xylose and galactose; in addition, trace amounts of rhamnose, arabinose, fucose, allose, fructose, glucose and mannose are found. Meanwhile, the gelidium pacificum okam polysaccharide A-11 disclosed by the invention has the advantages that the cytotoxicity of LPS-induced THP-1 is significantly inhibited, sothat the cells are prevented from being damaged; besides, the expression of signal factors MyD88 and TRAF-6 in an immune signaling pathway can be regulated so as to enhance human immunity.

The invention relates to a bacterial solution of intestinal florae of healthy people, and a preparation method and quality control of the bacterial liquid. The invention also relates to an applicationof combination of the bacterial solution of intestinal florae of healthy people and an immune signal pathway modulator in treating tumor patients to improve response of tumors to immunotherapy.

The invention belongs to the technical field of food detection, and discloses a method for detecting ochratoxin A based on a copper ion fluorescent probe indirect competition method. The method comprises the following steps: forming immune signal markers of carboxylate copper sulfide nano-particle-ochratoxin A monoclonal antibodies; fixing ochratoxin A antigens to a black polystyrene microporous plate, wherein after a sample to be detected is added, the ochratoxin A antigens in the sample to be detected and the ochratoxin A competitively bind to the ochratoxin A monoclonal antibodies on the markers; washing the immune signal markers of the carboxylate copper sulfide nano-particle-ochratoxin A monoclonal antibodies which are not bonded to the ochratoxin A antigens fixed to the black polystyrene microporous plate, dissolving out the copper ions which are marked by immune signals of the carboxylate copper sulfide nano-particle-ochratoxin A monoclonal antibodies bonded to the ochratoxin Aantigens fixed to the black polystyrene microporous plate, and adding a copper ion fluorescent probe to catalyze the copper ions to perform quantitative fluorescence detection. The method disclosed bythe invention is low in cost and easy to operate.

The invention relates to an application of a probiotic composition in preparation of a medicine for treating tumors. The probiotic comprises Bifidobacterium animalis subsp. Lactis. The medicine also comprises one or more tumor treatment medicines, such as an immune signal path regulator PD-1 / PDL-1 and the like, and the medicines are used for tumor immunotherapy.

The present invention relates to pharmaceutical compositions and use thereof for treating diseases. A pharmaceutical composition is provided. The pharmaceutical composition comprises an immune signaling pathway modulator and an amount of Lactobacillus rhamnosus in an amount sufficient to enhance a therapeutic response of a subject to the immune signaling pathway modulator. The invention belongs to the field of microbial medicines. The lactobacillus rhamnosus which is preserved in the China General Microbiological Culture Collection Center with the preservation number of CGMCC No.18639 is orally taken, so that the response rate of PD-1 treatment accepted by tumor patients can be improved, the development of tumors is inhibited, and the lifetime is prolonged; the oral treatment mode is simple and noninvasive, and no extra harm is caused to the body of a patient basically; the lactobacillus rhamnosus is resistant to acid and alkali, and can be stably colonized through a gastrointestinal tract environment; and the bacterial powder fermentation freeze-drying process is mature and stable.

The invention discloses a kit for detecting procalcitonin in blood and a preparation method. The kit comprises a solid-phase carrier coated with a captured antibody, a biotin-labeled detection antibody, fluorescein labeled streptavidin, a washing buffer solution and the like. The surface of a quartz needle is coated with a polysaccharide compound with biocompatibility, wherein the polysaccharide compound can effectively enhance the specific immune signal, and the amplification of a detection signal is realized by forming a plurality of fluorescein-streptavidin molecular layers on the surface of the polysaccharide compound; and according to the kit, SDS with relatively high washing capability and Triton-X100 are added in the washing buffer solution, and the ionic strength of the washing solution is improved, so that the non-specific interaction between the molecules is effectively controlled, the low background and the high signal-to-noise ratio of the detection result are further realized, and the sensitivity and accuracy of detection are improved.

The invention discloses application of recombinant vibrio parahaemolyticus flagellin in improvement of fish immunity. It is found that the recombinant vibrio parahaemolyticus flagellin can induce expression of related immune genes and participate in activation of corresponding immune signal channels, the immunity of fishes is remarkably improved, the recombinant vibrio parahaemolyticus flagellin is expected to be developed into a natural fish immunopotentiator or immunologic adjuvant, and then fish diseases caused by vibrio parahaemolyticus are prevented or treated. Therefore, the recombinantvibrio parahaemolyticus flagellin has a good application prospect in improving fish immunity and preparing a fish immunopotentiator or immunologic adjuvant.

The disclosure provides a tetra-specific antibody monomer having a N-terminal and a C-terminal, comprising in tandem from the N-terminal to the C-terminal, a first scFv domain at the N-terminal, a second scFv domain, a Fab domain, a Fc domain, and a third scFv at the C-terminal, wherein the first scFv domain, the second scFv domain, the Fab domain, and the third scFv domain each has a binding specificity against a different antigen. In one embodiment, the antigen is a tumor antigen, an immune signaling antigen, or a combination thereof. In one embodiment, the antigen includes CD19, CD3, CD137,4-1BB, and PD-L1. Multi-specific antibodies comprising the disclosed tetra-specific antibodies are also provided.

The present invention relates, in part, to bispecific chimeric proteins that find use in various immunotherapies based on various properties, including, for example, a dual immune cell recruitment andimmune signal delivery function.

The invention discloses a method for improving bacterial blight resistance of rice. A rice OsRLK1 gene is knocked out, or the OsRLK1 gene is inactivated, so that an OsRLK1 protein is inactivated. The invention discloses a new molecular mechanism for regulating and controlling disease resistance of the rice and provides a new method for improving bacterial blight resistance of the rice, a receptor-like kinase gene OsRLK1 in the rice is edited in a targeted manner by utilizing a genome, an immune signal of the rice can be activated, and the disease resistance of the rice is realized.

The invention belongs to the technical field of biology, and relates to application of BRI1 in plant immune signal verification and a method. The plant development related regulatory gene BRI1 is applied to plant immune signal verification for the first time. The immune function receptor protein and the receptor protein BRI1 are recombined to construct a recombinant protein; the recombinant protein can be specifically combined with exogenous PAMPs molecules and activate the expression of an arabidopsis thaliana development related reporter gene, and the immunostimulatory activity of the PAMPsmolecules to be detected is determined through the expression quantity of the reporter gene. According to the method, the boundary of plant immunity and development research is broken through, quantitative analysis of the activation capacity of a single immune signal on receptor protein of brassinolide is achieved by detecting brassinolide related signals under the condition that multiple excitonsexist, effectiveness of different immune elements in the multi-antigen recombinant immune protein can be effectively verified. And a new technical means is provided for action mechanism research andbotanical research of recombinant immune protein.

The disclosure provides a tetra-specific antibody monomer having a N-terminal and a C-terminal, comprising in tandem from the N-terminal to the C-terminal, a first scFv domain at the N-terminal, a Fabdomain, a Fc domain, a second scFv domain, and a third scFv at the C-terminal, wherein the first scFv domain, the Fab domain, the second scFv domain, and the third scFv domain each has a binding specificity against a different antigen. In one embodiment, the antigen is a tumor antigen, an immune signaling antigen, or a combination thereof. Multi-specific antibodies comprising the disclosed tetra-specific antibodies are also provided.

Immune-polyelectrolyte multilayers (iPEMs) that can be made entirely from immune signal compounds are provided. The iPEMs are formed from first layer of a first immune signal compound, and a second layer of the first immune signal compound or a second immune signal compound disposed on the first layer of the first immune signal compound. The immune signal compounds are peptides, polypeptides, nucleic acids, charged derivatives thereof. Combinations of the immune signal compounds may be in adjacent layers. The first immune signal compound and the second immune signal compound have oppositely charged domains. iPEMs can be formed on or include a substrate, such as a sacrificial substrate, which allows for the formation of a three-dimensional void which can hold various other compounds for use in modulating immune responses. The iPEMs are for use in either stimulating an immune response to one or more antigens, or inducing tolerance to one or more antigens. Methods of stimulating immune responses, or inducing tolerance using the iPEMs, are also provided.

Compositions and methods for multi-specific protein complexes comprising an interleukin-15 (IL-15) domain comprising an N72D mutation (IL-15N72D), a IL-15 receptor alpha sushi-binding domain (IL-15RαSu), an immunoglobulin Fc domain, and a mutated transforming growth factor-beta receptor type 2 (TGFβRII) domain, wherein the mutated TGFβRII domain has a N->Q mutation in positions 47, 71, and 131 respectively. The IL-15RαSu domain, the Fc domain, and the mutated TGFβRII domain are sequentially linked by amide bonds. Preferably, contemplated complexes further include a binding domain that specifically binds to a disease antigen, immune checkpoint molecule, or immune signaling molecule.

Methods and compositions disclosed herein generally relate to compositions and methods for suppressing hematopoietic stem and progenitor cells (HSPCs) and the treatment of diseases or disorders involving UBE2N, such as cancers, including disorders such as myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML) and chronic inflammatory disorders. Particular aspects relate to treating, e.g. acute myelomonocytic leukemia (AML-M4) and acute monocytic leukemia (AML-M5). Particular aspects of the invention relate to determining an individual in need of treatment who can be treated with a UBE2N inhibitor, such as an individual having AML-M4 and / or AML-M5. The invention further relates to using a UBE2N inhibitor to treat a disease or disorder characterized by malignant hematopoietic cells, as well as other cancers, and chronic inflammatory disorders, and as immune checkpoint regulators.

The invention belongs to the technical field of medicine, and specifically relates to applications of cyclic dinucleotide cGAMP in preparation of health products. According to the present invention, the research results show that the cyclic dinucleotide cGAMP as the human body natural immune signal pathway activator and the natural immune system enhancer can achieve the important disease preventing and body building immune defense effects of multiple virus infection prevention, tumor occurrence and development inhibition, Alzheimer disease prevention and the like by enhancing the immunity of the innate immune system; the acute animal toxicity test results show that the cGAMP does not present the significant acute toxicity, such that the cGAMP used as the endogenous second messenger capable of regulating the natural immune reaction has potential applications of virus infection prevention, virus infection resistance and tumor resistance; and the cGAMP can be used for preparing the additive of health products or special dietary.

The invention belongs to the field of biotechnology and immunology, and particularly relates to a duck-derived innate immunomodulatory protein DDX3X for regulating and controlling an innate immune signal pathway in duck embryo fibroblasts (DEF), participating in antiviral reaction and playing a role in duck antiviral infection. It is proved in the DEF that overexpression of duck-derived DDX3X caninduce generation of duck I-type interferon by activating transcription factors including IRF1 and Nf-kappa B; after the background expression of DDX3X is interfered, the activity of poly(I: C) and DTMUV induced I-type interferon is also obviously reduced; and the overexpression of DDX3X can be used for remarkably inhibiting the proliferation of the DTMUV (Duck tembusu virus). The invention further discloses that the duck-derived DDX3X is expected to become a novel target for treating duck inflammatory diseases, and can be applied to the preparation of drugs with the effect of inhibiting DTMUVproliferation; the duck-derived DDX3X can also be used as an immunomodulator for duck virus diseases.

The invention relates to application of EFTUD2 and an Epro-LUC-HepG2 modeling method. The EFTUD2 protein can adjust the generation of key signal molecules RIG-1 and MDA5 mRNA in an innate immune signal path through a splicing effect, so that the generation of interferon stimulating genes (ISGs) is influenced to inhibit HBV replication. According to the application, a stable compound screening cellmodel is established by taking EFTUD2 as a target spot so that a new molecular targeted drug can be researched and explored. On the basis of the model, compounds capable of up-regulating EFTUD2 geneexpression are screened, and more treatment options are provided for HBV chronic infection patients, especially patients with poor clinical IFN-alpha treatment response.

The invention discloses a novel dengue fever microneedle vaccine and a preparation method thereof. The inactivated virus vaccine is prepared by virus culture, virus concentration, virus inactivation and the like, and the novel dengue fever microneedle vaccine is prepared by preparing a reversing mold, preparing a microneedle and the like. The soluble microneedle painless vaccine prepared by the method cannot cause pain, and is safer than subcutaneous injection. The inactivated antigen is injected into muscle by a syringe, and is delivered into skin rich in immune signaling cells by means of microneedle injection, and a better vaccine delivery effect is achieved. The solid-state microneedle coated medicine can be stored at room temperature without refrigeration, and the transportation and storage cost can be greatly reduced in comparison with those of liquid injection medicines.

Compositions and methods for multispecific protein complexes comprising: an interleukin-15 (IL-15) domain (IL-15N72D) comprising a mutation of N72D, an IL-15 receptor [alpha] suhi-binding domain (IL-15R [alpha] Su), an immunoglobulin Fc domain, and a mutated transforming growth factor-[beta] receptor type 2 (TGF [beta] RII) domain, wherein the mutated TGF [beta] RII domain has N-> Q mutations at positions 47, 71 and 131, respectively. The IL-15R [alpha] Su structural domain, the Fc structural domain and the mutant TGF [beta] RII structural domain are sequentially connected through amido bonds. Preferably, the complexes contemplated further comprise a binding domain that specifically binds to a disease antigen, an immune checkpoint molecule or an immune signaling molecule.

The invention belongs to the field of biotechnology, and relates to the application and method of BRI1 in the verification of plant immune signals. In the present invention, the plant development-related regulatory gene BRI1 is applied to the verification of plant immune signals for the first time. The recombinant protein was constructed by recombining the immune function receptor protein and the receptor protein BRI1; the recombinant protein can specifically bind to exogenous PAMPs molecules and activate the expression of Arabidopsis development-related reporter genes. To measure the immune stimulating activity of PAMPs molecules. The method of the invention breaks the boundaries of plant immunity and development research, and realizes the quantitative analysis of the activation ability of a single immune signal to its receptor protein under the condition of the presence of multiple elicitors by examining the brassinosteroid-related signals, which can effectively The verification of the effectiveness of different immune components in the multi-antigen recombinant immune protein provides a new technical means for the study of the mechanism of action of the recombinant immune protein and botany research.

The invention discloses an application of TgCPC1 in preparation of a drug for inhibiting inflammation. The invention is obtained based on the achievement of the inventors for the first time that the transfection TgCPC1 can inhibit a natural immune NFkappaB signal pathway. The inventors provided by the invention find that the transfection TgCPC1 plasmid can inhibit the activity of a NFkappaB promoter induced by MyD88, TRAF6, IKKalpha, IKKbeta and P65, and the inhibitory effect increases with the increase of a TgCPC1 plasmid concentration; the transfection TgCPC1 plasmid can inhibit the expression of IL-1, IL-6, IL-8, IL-12 and TNFalpha at the downstream of the NFkappaB; and the transfection TgCPC1 plasmid can inhibit p65 phosphorylation. The results reveal that the TgCPC1 has an inhibitoryeffect on innate immunity, and lays a necessary foundation for the application of the TgCPC1 in preparation of the drug for inhibiting the inflammation.

Immune-polyelectrolyte multilayers (iPEMs) that can be made entirely from immune signal compounds are provided. iPEMs are formed from first layer of a first immune signal compound, and a second layer of the first immune signal compound or a second immune signal compound disposed on the first layer of the first immune signal compound. The immune signal compounds are peptides, polypeptides, nucleic acids, charged derivatives thereof. Combinations of the immune signal compounds may be in adjacent layers. The first immune signal compound and the second immune signal compound have oppositely charged domains. iPEMs can be formed on or include a substrate, such as a sacrificial substrate, which allows for the formation of a three-dimensional void which can hold various other compounds for use in modulating immune responses. The iPEMs are for use in either stimulating an immune response to one or more antigens, or inducing tolerance to one or more antigens. Methods of stimulating immune responses, or inducing tolerance using the iPEMs, are also provided.